Stay updated on Patisiran for hATTR Amyloidosis Clinical Trial
Sign up to get notified when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.

Latest updates to the Patisiran for hATTR Amyloidosis Clinical Trial page
- CheckyesterdayNo Change Detected
- Check9 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference1.0%
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed information about an expanded access program for patisiran and the inclusion of new terminology related to TTR-mediated amyloidosis. Additionally, the version number has been updated from v2.14.4 to v2.15.0.SummaryDifference19%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference1.0%
- Check66 days agoChange DetectedDifference0.8%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference3%
- Check88 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference3%
Stay in the know with updates to Patisiran for hATTR Amyloidosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Patisiran for hATTR Amyloidosis Clinical Trial page.